β-Amyloid 42/40 ratio and kalirin expression in Alzheimer disease with psychosis

Neurobiology of Aging

Volumn 33, Issue 12, 2012, Pages 2807-2816

  Murray, Patrick S ^a,b   Kirkwood, Caitlin M ^a   Gray, Megan C ^a   Ikonomovic, Milos D ^a,b   Paljug, William R ^a   Abrahamson, Eric E ^a   Henteleff, Ruth A ^a   Hamilton, Ronald L ^a   Kofler, Julia K ^a   Klunk, William E ^a   Lopez, Oscar L ^a   Penzes, Peter ^c   Sweet, Robert A ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

amyloid; Alzheimer disease; Kalirin; Psychosis

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; HUNTINGTIN; KALIRIN; KALIRIN 12; KALIRIN 7; KALIRIN 9; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; CADAVER; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GRAY MATTER; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NEUROPATHOLOGY; OCCIPITAL CORTEX; PARIETAL CORTEX; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PSYCHOSIS; SUPERIOR FRONTAL GYRUS; SUPERIOR TEMPORAL GYRUS;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANALYSIS OF VARIANCE; CEREBRAL CORTEX; CHI-SQUARE DISTRIBUTION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; MALE; PEPTIDE FRAGMENTS; PROTEIN ISOFORMS; PROTEIN-SERINE-THREONINE KINASES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS;

EID: 84866759278     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2012.02.015     Document Type: Article

References (67)

1. Alam M.R., Johnson R.C., Darlington D.N., Hand T.A., Mains R.E., Eipper B.A. Kalirin, a cytosolic protein with spectrin-like and GDP/GTP exchange factor-like domains that interacts with peptidylglycine alpha-amidating monooxygenase, an integral membrane peptide-processing enzyme. J. Biol. Chem 1997, 272:12667-12675.
2. Almeida C.G., Tampellini D., Takahashi R.H., Greengard P., Lin M.T., Snyder E.M., Gouras G.K. Beta-amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses. Neurobiol. Dis 2005, 20:187-198.
3. Bacanu S.A., Devlin B., Chowdari K.V., DeKosky S.T., Nimgaonkar V.L., Sweet R.A. Heritability of psychosis in Alzheimer disease. Am. J. Geriatr. Psychiatry 2005, 13:624-627.
4. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991, 82:239-259.
5. Bruen P.D., McGeown W.J., Shanks M.F., Venneri A. Neuroanatomical correlates of neuropsychiatric symptoms in Alzheimer's disease. Brain 2008, 131:2455-2463.
6. Cahill M.E., Xie Z., Day M., Photowala H., Barbolina M.V., Miller C.A., Weiss C., Radulovic J., Sweatt J.D., Disterhoft J.F., Surmeier D.J., Penzes P. Kalirin regulates cortical spine morphogenesis and disease-related behavioral phenotypes. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:13058-13063.
7. Cerione R.A., Zheng Y. The Dbl family of oncogenes. Curr. Opin. Cell Biol 1996, 8:216-222.
8. Counts S.E., Nadeem M., Lad S.P., Wuu J., Mufson E.J. Differential expression of synaptic proteins in the frontal and temporal cortex of elderly subjects with mild cognitive impairment. J. Neuropathol. Exp. Neurol 2006, 65:592-601.
9. Cullen W.K., Suh Y.H., Anwyl R., Rowan M.J. Block of LTP in rat hippocampus in vivo by beta-amyloid precursor protein fragments. Neuroreport 1997, 8:3213-3217.
10. DeKosky S.T., Scheff S.W. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann. Neurol 1990, 27:457-464.
11. Deo A.J., Cahill M.E., Li S., Goldszer I., Henteleff R., VanLeeuwen J.E., Rafalovich I., Gao R., Stachowski E.K., Sampson A.R. Increased Expression of Kalirin-9 in the Auditory Cortex of Schizophrenia Subjects: its role in dendritic pathology. Neurobiol. Dis 2012, 45:796-803.
12. Emanuel J.E., Lopez O.L., Houck P.R., Becker J.T., Weamer E.A., DeMichele-Sweet M.A., Kuller L., Sweet R.A. Trajectory of Cognitive Decline as a Predictor of Psychosis in Early Alzheimer Disease in the Cardiovascular Health Study. Am. J. Geriatr. Psychiatry 2011, 19:160-168.
13. Farber N.B., Rubin E.H., Newcomer J.W., Kinscherf D.A., Miller J.P., Morris J.C., Olney J.W., McKeel D.W. Increased neocortical neurofibrillary tangle density in subjects with Alzheimer disease and psychosis. Arch. Gen. Psychiatry 2000, 57:1165-1173.
14. Gravina S.A., Ho L., Eckman C.B., Long K.E., Otvos L., Younkin L.H., Suzuki N., Younkin S.G. Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). J. Biol. Chem 1995, 270:7013-7016.
15. Grutzendler J., Helmin K., Tsai J., Gan W.-B. Various dendritic abnormalities are associated with fibrillar amyloid deposits in Alzheimer's disease. Ann. N. Y. Acad. Sci 2007, 1097:30-39.
16. Hsia A.Y., Masliah E., McConlogue L., Yu G.Q., Tatsuno G., Hu K., Kholodenko D., Malenka R.C., Nicoll R.A., Mucke L. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:3228-3233.
17. Ikonomovic M.D., Klunk W.E., Abrahamson E.E., Mathis C.A., Price J.C., Tsopelas N.D., Lopresti B.J., Ziolko S., Bi W., Paljug W.R. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008, 131:1630-1645.
18. Jacobsen J.S., Wu C.C., Redwine J.M., Comery T.A., Arias R., Bowlby M., Martone R., Morrison J.H., Pangalos M.N., Reinhart P.H., Bloom F.E. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:5161-5166.
19. Joachim C.L., Duffy L.K., Morris J.H., Selkoe D.J. Protein chemical and immunocytochemical studies of meningovascular beta-amyloid protein in Alzheimer's disease and normal aging. Brain Res 1988, 474:100-111.
20. Johnson R.C., Penzes P., Eipper B.A., Mains R.E. Isoforms of kalirin, a neuronal Dbl family member, generated through use of different 5'- and 3'-ends along with an internal translational initiation site. J. Biol. Chem 2000, 275:19324-19333.
21. Kashani A., Lepicard E., Poirel O., Videau C., David J.P., Fallet-Bianco C., Simon A., Delacourte A., Giros B., Epelbaum J., Betancur C., El Mestikawy S. Loss of VGLUT1 and VGLUT2 in the prefrontal cortex is correlated with cognitive decline in Alzheimer disease. Neurobiol. Aging 2008, 29:1619-1630.
22. Kim J., Onstead L., Randle S., Price R., Smithson L., Zwizinski C., Dickson D.W., Golde T., McGowan E. Abeta40 inhibits amyloid deposition in vivo. J. Neurosci 2007, 27:627-633.
23. Koffie R.M., Meyer-Luehmann M., Hashimoto T., Adams K.W., Mielke M.L., Garcia-Alloza M., Micheva K.D., Smith S.J., Kim M.L., Lee V.M., Hyman B.T., Spires-Jones T.L. Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:4012-4017.
24. Kotrla K.J., Chacko R.C., Harper R.G., Jhingran S., Doody R. SPECT findings on psychosis in Alzheimer's disease. Am. J. Psychiatry 1995, 152:1470-1475.
25. Kuperstein I., Broersen K., Benilova I., Rozenski J., Jonckheere W., Debulpaep M., Vandersteen A., Segers-Nolten I., Van Der Werf K., Subramaniam V., Braeken D., Callewaert G., Bartic C., D'Hooge R., Martins I.C., Rousseau F., Schymkowitz J., De Strooper B. Neurotoxicity of Alzheimer's disease Aβ peptides is induced by small changes in the Aβ42 to Aβ40 ratio. EMBO J 2010, 29:3408-3420.
26. Lopez O.L., Wisniewski S.R., Becker J.T., Boller F., DeKosky S.T. Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease. Arch. Neurol 1999, 56:1266-1272.
27. Matsuzaki M. Factors critical for the plasticity of dendritic spines and memory storage. Neurosci. Res 2007, 57:1-9.
28. May V., Schiller M.R., Eipper B.A., Mains R.E. Kalirin Dbl-homology guanine nucleotide exchange factor 1 domain initiates new axon outgrowths via RhoG-mediated mechanisms. J. Neurosci 2002, 22:6980-6990.
29. McKeith I., Mintzer J., Aarsland D., Burn D., Chiu H., Cohen-Mansfield J., Dickson D., Dubois B., Duda J.E., Feldman H., Gauthier S., Halliday G., Lawlor B., Lippa C., Lopez O.L., Carlos Machado J., O'Brien J., Playfer J., Reid W. Dementia with Lewy bodies. Lancet Neurol 2004, 3:19-28. International Psychogeriatric Association Expert Meeting on DLB.
30. Mega M.S., Lee L., Dinov I.D., Mishkin F., Toga A.W., Cummings J.L. Cerebral correlates of psychotic symptoms in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 2000, 69:167-171.
31. Mirra S.S., Heyman A., McKeel D., Sumi S.M., Crain B.J., Brownlee L.M., Vogel F.S., Hughes J.P., Van Belle G., Berg L. Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991, 41:479-486. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD).
32. Mucke L., Masliah E., Yu G.Q., Mallory M., Rockenstein E.M., Tatsuno G., Hu K., Kholodenko D., Johnson-Wood K., McConlogue L. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci 2000, 20:4050-4058.
33. Murray M.M., Bernstein S.L., Nyugen V., Condron M.M., Teplow D.B., Bowers M.T. Amyloid beta protein: Abeta40 inhibits Abeta42 oligomerization. J. Am. Chem. Soc 2009, 131:6316-6317.
34. Näslund J., Haroutunian V., Mohs R., Davis K.L., Davies P., Greengard P., Buxbaum J.D. Correlation between elevated levels of amyloid -peptide in the brain and cognitive decline. JAMA 2000, 283:1571-1577.
35. Paulsen J.S., Salmon D., Thal L., Romero R., Weisstein-Jenkins C., Galasko D., Hofstetter C., Thomas R., Grant I., Jeste D. Incidence of and risk factors for hallucinations and delusions in patients with probable. Adv. Neurol 2000, 54:1965-1971.
36. Penzes P., Beeser A., Chernoff J., Schiller M.R., Eipper B.A., Mains R.E., Huganir R.L. Rapid induction of dendritic spine morphogenesis by trans-synaptic ephrinB-EphB receptor activation of the Rho-GEF kalirin. Neuron 2003, 37:263-274.
37. Penzes P., Cahill M.E., Jones K.A., VanLeeuwen J.E., Woolfrey K.M. Dendritic spine pathology in neuropsychiatric disorders. Nat. Neurosci 2011, 14:285-293.
38. Penzes P., Johnson R.C., Alam M.R., Kambampati V., Mains R.E., Eipper B.A. An isoform of kalirin, a brain-specific GDP/GTP exchange factor, is enriched in the postsynaptic density fraction. J. Biol. Chem 2000, 275:6395-6403.
39. Penzes P., VanLeeuwen J.E. Impaired regulation of synaptic actin cytoskeleton in Alzheimer's disease. Brain Res. Rev 2011, 67:184-192.
40. Rakic P., Bourgeois J.P., Eckenhoff M.F., Zecevic N., Goldman-Rakic P.S. Concurrent overproduction of synapses in diverse regions of the primate cerebral cortex. Science 1986, 232:232-235.
41. Reddy P.H., Mani G., Park B.S., Jacques J., Murdoch G., Whetsell W., Kaye J., Manczak M. Differential loss of synaptic proteins in Alzheimer's disease: implications for synaptic dysfunction. J. Alzheimers Dis 2005, 7:103-118.
42. Ropacki S.A., Jeste D.V. Epidemiology of and risk factors for psychosis of Alzheimer's disease: a review of 55 studies published from 1990 to 2003. Am. J. Psychiatry 2005, 162:2022-2030.
43. Roselli F., Tirard M., Lu J., Hutzler P., Lamberti P., Livrea P., Morabito M., Almeida O.F. Soluble beta-amyloid1-40 induces NMDA-dependent degradation of postsynaptic density-95 at glutamatergic synapses. J. Neurosci 2005, 25:11061-11070.
44. Scarmeas N., Brandt J., Albert M., Hadjigeorgiou G., Papadimitriou A., Dubois B., Sarazin M., Devanand D., Honig L., Marder K., Bell K., Wegesin D., Blacker D., Stern Y. Delusions and hallucinations are associated with worse outcome in Alzheimer disease. Arch. Neurol 2005, 62:1601-1608.
45. Scheff S.W., Price D.A. Alzheimer's disease-related alterations in synaptic density: neocortex and hippocampus. J. Alzheimers Dis 2006, 9:101-115.
46. Selkoe D.J. Alzheimer's disease is a synaptic failure. Science 2002, 298:789-791.
47. Shankar G.M., Bloodgood B.L., Townsend M., Walsh D.M., Selkoe D.J., Sabatini B.L. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci 2007, 27:2866-2875.
48. Shankar G.M., Li S., Mehta T.H., Garcia-Munoz A., Shepardson N.E., Smith I., Brett F.M., Farrell M.A., Rowan M.J., Lemere C.A., Regan C.M., Walsh D.M., Sabatini B.L., Selkoe D.J. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med 2008, 14:837-842.
49. Staff R.T., Shanks M.F., Macintosh L., Pestell S.J., Gemmell H.G., Venneri A. Delusions in Alzheimer's disease: spet evidence of right hemispheric dysfunction. Cortex 1999, 35:549-560.
50. Sultzer D.L., Mahler M.E., Mandelkern M.A., Cummings J.L., Van Gorp W.G., Hinkin C.H., Berisford M.A. The relationship between psychiatric symptoms and regional cortical metabolism in Alzheimer's disease. J. Neuropsychiatry Clin. Neurosci 1995, 7:476-484.
51. Suzuki N., Iwatsubo T., Odaka A., Ishibashi Y., Kitada C., Ihara Y. High tissue content of soluble beta 1-40 is linked to cerebral amyloid angiopathy. Am. J. Pathol 1994, 145:452-460.
52. Sweet R.A., Bennett D.A., Graff-Radford N.R., Mayeux R. Assessment and familial aggregation of psychosis in Alzheimer's disease from the National Institute on Aging Late Onset Alzheimer's Disease Family Study. Brain 2010, 133:1155-1162.
53. Sweet R.A., Hamilton R.L., Butters M.A., Mulsant B.H., Pollock B.G., Lewis D.A., Lopez O.L., DeKosky S.T., Reynolds C.F. Neuropathologic correlates of late-onset major depression. Neuropsychopharmacology 2004, 29:2242-2250.
54. Sweet R.A., Hamilton R.L., Healy M.T., Wisniewski S.R., Henteleff R., Pollock B.G., Lewis D.A., DeKosky S.T. Alterations of striatal dopamine receptor binding in Alzheimer disease are associated with Lewy body pathology and antemortem psychosis. Arch. Neurol 2001, 58:466-472.
55. Sweet R.A., Hamilton R.L., Lopez O.L., Klunk W.E., Wisniewski S.R., Kaufer D.I., Healy M.T., DeKosky S.T. Psychotic symptoms in Alzheimer's disease are not associated with more severe neuropathologic features. Int. Psychogeriatr 2000, 12:547-558.
56. Sweet R.A., Nimgaonkar V.L., Devlin B., Lopez O.L., DeKosky S.T. Increased familial risk of the psychotic phenotype of Alzheimer disease. Neurology 2002, 58:907-911.
57. Sweet R.A., Panchalingam K., Pettegrew J.W., McClure R.J., Hamilton R.L., Lopez O.L., Kaufer D.I., DeKosky S.T., Klunk W.E. Psychosis in Alzheimer disease: postmortem magnetic resonance spectroscopy evidence of excess neuronal and membrane phospholipid pathology. Neurobiol. Aging 2002, 23:547-553.
58. Tariot P.N., Mack J.L., Patterson M.B., Edland S.D., Weiner M.F., Fillenbaum G., Blazina L., Teri L., Rubin E., Mortimer J.A., et al. The behavior rating scale for dementia of the consortium to establish a registry for Alzheimer's disease. The behavioral pathology committee of the consortium to establish a registry for Alzheimer's disease. Am. J. Psychiatry 1995, 152:1349-1357.
59. Terry R.D., Masliah E., Salmon D.P., Butters N., DeTeresa R., Hill R., Hansen L.A., Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol 1991, 30:572-580.
60. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., Selkoe D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002, 416:535-539.
61. Walsh D.M., Selkoe D.J. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 2004, 44:181-193.
62. Wang H.W., Pasternak J.F., Kuo H., Ristic H., Lambert M.P., Chromy B., Viola K.L., Klein W.L., Stine W.B., Krafft G.A., Trommer B.L. Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res 2002, 924:133-140.
63. Wu C.C., Chawla F., Games D., Rydel R.E., Freedman S., Schenk D., Young W.G., Morrison J.H., Bloom F.E. Selective vulnerability of dentate granule cells prior to amyloid deposition in PDAPP mice: digital morphometric analyses. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:7141-7146.
64. Xie Z., Srivastava D.P., Photowala H., Kai L., Cahill M.E., Woolfrey K.M., Shum C.Y., Surmeier D.J., Penzes P. Kalirin-7 controls activity-dependent structural and functional plasticity of dendritic spines. Neuron 2007, 56:640-656.
65. Youn H.S., Jeoung M.K., Koo Y.B., Ji H., Markesbery W.R., Ji I., Ji T.H. Kalirin is under-expressed in Alzheimer's disease hippocampus. J. Alzheimers Dis 2007, 11:385-397.
66. Youn H.S., Ji I., Ji H.P., Markesbery W.R., Ji T.H. Under-expression of kalirin-7 increases iNOS activity in cultured cells and correlates to elevated iNOS activity in Alzheimer's disease hippocampus. J. Alzheimers Dis 2007, 12:271-281.
67. Zhao L., Ma Q.L., Calon F., Harris-White M.E., Yang F., Lim G.P., Morihara T., Ubeda O.J., Ambegaokar S., Hansen J.E. Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease. Nature 2006, 9:234-242.